¹ **Identification of rare missense variants reducing cathepsin O** ² **secretion in families with intracranial aneurysm**

- 3
- 4 Milène Freneau^{1,*}, Raphael Blanchet^{1,*}, Sandro Benichi¹, Mary-Adel Mrad¹, Surya Prakash
- 5 Rao Batta¹, Marc Rio¹, Stéphanie Bonnaud¹, Pierre Lindenbaum¹, Fabien Laporte¹, Stéphane
- 6 Cuénot², Thibaud Quillard¹, Sandrine Morel^{3, 4}, Brenda R. Kwak³, Philippe Bijlenga⁴, Jean-
- 7 François Deleuze⁵, Christian Dina¹, Maxence Bodet¹, Stéphanie Chatel¹, Emmanuelle
- 8 Bourcereau⁶, Solène Jouan⁶, Arturo Consoli⁷, Cyril Dargazanli⁸, Julien Ognard⁹, ICAN Study
- 9 Group, Hubert Desal^{1,6}, Anne-Clémence Vion¹, Romain Bourcier^{1,6,*}, Gervaise Loirand^{1,*,#},
- 10 Richard Redon^{1,*,#}.
- 11
- 12 ¹ Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes,
- 13 France
- ² Nantes Université, CNRS, Institut des Matériaux de Nantes Jean Rouxel, IMN, F-44000
- 15 Nantes, France
- ³ Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, CH-
- 17 1211 Geneva, Switzerland
- ⁴ Neurosurgery Division, Department of Clinical Neurosciences, Faculty of Medicine, Geneva
- 19 University Hospitals and University of Geneva, Geneva, Switzerland.
- 20 ⁵ Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine
- 21 (CNRGH), F-91057 Evry, France
- ⁶ Department of Neuroradiology, CHU Nantes, F-44000 Nantes, France
- ⁷ Department of Interventional Neuroradiology, Foch Hospital, University Versailles Saint-
- 24 Quentin en Yvelines, F-92073 Suresnes, France
- ⁸ Department of Neuroradiology, University Hospital Centre Montpellier, F-34000 Montpellier,
- 26 France
- 27 ⁹ Radiology Department, University Hospital, F-29000 Brest, France
- * 28 These authors contributed equally to this work as first and last authors
- 29
- 30 [#]Correspondence: Gervaise Loirand, UMR Inserm 1087/Cnrs 6291, IRS-UN, 8 Quai
- 31 Moncousu, BP 70721, 44007 Nantes cedex 1, France. Phone: 33 2 28 08 01 16; Email:
- 32 [gervaise.loirand@univ-nantes.fr\)](mailto:gervaise.loirand@univ-nantes.fr). Or to: Richard Redon, UMR Inserm 1087/Cnrs 6291, IRS–
- 33 UN, 8 Quai Moncousu, BP 70721, 44007 Nantes cedex 1, France. Phone: 33 2 28 08 01 10;
- 34 Email: [\(richard.redon@univ-nantes.fr\)](mailto:richard.redon@univ-nantes.fr)
- 35
- 36 **Short title:** *CTSO* and intracranial aneurysm
- 37 **Conflict of interest statement:** The authors have declared that no conflict of interest exists.
- 38 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

ABSTRACT

 Intracranial aneurysm (IA) is a common cerebrovascular abnormality characterized by localized dilation and wall thinning in intracranial arteries, which can rupture and lead to fatal subarachnoid hemorrhage. Although the pathophysiology of IA remains largely unknown, increasing evidence suggests that genetic susceptibility plays a predominant role. Here, we combined whole exome sequencing and identity-by-descent analyses with functional investigations to identify rare functional variants associated to IA in families with multiple affected subjects. We identified two rare missense variants in the *CTSO* gene in two large 47 pedigrees. We found that the cysteine-type papain-like cathepsin O (CTSO) encoded by *CTSO* is expressed in the wall of human IA domes. Stretching of vascular smooth muscle cells (VSMC) induced secretion of CTSO, which acted as an extracellular protease controlling VSMC migration and adhesion to the extracellular matrix. CTSO depletion, as well as expression of the two CTSO variants, which are poorly secreted, increased the amount of fibronectin. In addition, CTSO depletion increased VSMC stiffness, which was reduced by the addition of exogenous CTSO. Collectively, our findings identify CTSO as a potential new player in arterial remodeling, regulating fibronectin deposition and VSMC function, supporting the causal role of rare coding *CTSO* variants in familial forms of IA.

INTROCUCTION

 Intracranial aneurysm (IA) is a generally asymptomatic localized dilation associated with thinning and structural defects of the intracranial arterial wall affecting 1-5% of the general 60 population (1). The main risk of IA is its unpredictable rupture, responsible for \sim 36,000 of subarachnoid hemorrhage cases per year in Europe and a major cause of sudden death in "young healthy" subjects, in particular in women (peak of age: 50-60 years) (2, 3). Although hypertension, ageing, female sex, smoking, excessive alcohol consumption and family history of IA have been identified as risk factors predisposing to IA, the mechanisms underlying IA formation, growth and rupture are mostly unknown. However, local hemodynamic constraints of shear stress and pressure are assumed to play a key role (4). The aggregation of patients in IA families suggests that genetic factors contribute to disease susceptibility, and identifying these factors might be beneficial for at-risk patients before IA rupture (5, 6). Genome-wide association studies have identified several common risk loci associated with IA (7-10). However, the identification of specific genes or causal molecular pathways remains largely inconclusive and these common alleles together only explain a small fraction of the risk attributable to genetics for IA in the general population. On the other hand, whole-exome sequencing (WES) has the potential to detect rare coding variants that have large effect and induce a high risk of developing IA. Identifying such variants also could provide valuable insights into IA pathophysiology and pave the way for new diagnostic or therapeutic strategies. Indeed, recent studies have demonstrated the usefulness of familial approaches based on WES to improve knowledge on the molecular mechanisms underlying IA formation and rupture from the discovery of rare predisposing variants such as *RNF213* (11), *THSD1* (12), *LOXL2* (13), *PCNT* (14), *ARHGEF17* (15), *ANGPTL6* (16)*,* and *PPIL4* (17). In the present study, by combining WES and identity-by-descent (IBD) analysis, we identified rare coding variants in the Cathepsin O gene (*CTSO* [MIM: 600550]) in two familial cases of IA. CTSO is one of the 11 cysteine-type papain-like cathepsins identified in humans about which almost nothing is known (18). Our functional analysis revealed that CTSO controls vascular smooth muscle cell (VSMC) migration and adhesion to the extracellular matrix (ECM). Furthermore, CTSO depletion increased VSMC stiffness. These finding suggest that the increased susceptibility to IA induced by *CTSO* variants is likely related to their primary effects on vascular tissue, and more particularly on the media layer of the wall of cerebral arteries.

RESULTS

Identification of one rare coding variant affecting *CTSO* **in a familial case of IA**

 We first recruited a large family (pedigrees are available on request) with 6 definite carriers of IA in two generations, among whom two had a history of IA rupture. In this family, there were also 4 relatives with suspected IA (3 because of unexplained sudden death and 1 with a doubtful ectasia on MRI, see Figure S1A), 3 individuals with unknown phenotypes in the absence of MRI screening, and 19 subjects without IA detected on MRI. Among the definite carriers of IA, all were females and 3 were carriers of multiple IA (with a maximum of 4 IAs detected for 98 1 subject). Of the twelve IAs detected in the family, 6 were located in the MCA territory (50%), 3 in the ACA (25%), 2 in the PCA (16%), and 1 in the ICA territory (9%)(Figure 1A and B). The median maximal diameter of IA was 4 mm (min 3 mm, max 8 mm). We applied whole- exome sequencing to 3 affected members of the family. Out of the 77 to 107 rare non- synonymous or splicing variants detected in each 3 whole exomes, we found that only 8 were shared between the 3 affected relatives (Table S1 and S2). IBD analysis on all available relatives revealed that only one of the 8 variants resides within a shared haplotype - located at 4q32 - between the 6 affected subjects (Table S1 and S3). We then confirmed this finding by capillary sequencing. This missense variant in the *CTSO* gene - *CTSO* c.946G>A (p.Val316Ile) - is

 reported with a Genomic Evolutionary Rate Profiling (GERP) score of 5.68 and predicted *in silico* as damaging for CTSO protein structure and function by both PolyPhen-2 and SIFT (Table 1).

A second familial case of IA associated with rare *CTSO* **coding variant**

 To further investigate the putative involvement of *CTSO* in IA susceptibility, we then screened for rare functional variants within this gene among 93 additional index cases with familial forms of IA, for which WES data were available in-house. We found one additional rare missense variant, *CTSO* c.128C>T (p.Ala43Val), in one case (Table 1). The corresponding family comprised 4 IA carriers (3 females and 1 males), among whom one carried 2 IAs. The median maximal diameter of IA was 5 mm (min 4 mm, max 9 mm). Three IAs were located in the MCA territory, one in the ACA and one in the ICA territory, while in one case the location was undetermined. undetermined. By capillary sequencing, we tested the *CTSO* c.128C>T variant among family members and detected it in the 3 tested IA carriers but in none of their 6 non- affected relatives (including a subject with uncertain phenotype, Figure S1B). This variant, reported with a GERP score of 3.67, was predicted *in silico* as damaging by PolyPhen-2 but not by SIFT (Table 1).

Clinical characteristics and exposition to risk factors according to *CTSO* **status**

 When comparing subgroups of individuals with or without *CTSO* variant and carrying or not IA among the two families members, we observed a higher proportion of subjects with history of high blood pressure among the IA carriers (p=0.013) while we found no significant differences regarding age, proportion of women, smoking habits, history of ischaemic stroke, level of alcohol consumption, history of diabetes or dyslipidaemia, treatment with statin, antiplatelet, oral anticoagulant and anti-inflammatory medication (Table 2).

CTSO is expressed in cerebral arteries

 To explore the putative implication of CTSO in IA pathophysiology, we first sought to investigate the expression of CTSO in cerebral arteries. *Ctso* mRNA was found at a similar level in cerebral arteries of WKY rats and in arteries from spontaneously hypertensive rat (SHR) and stroke prone SHR (SPSHR), suggesting that *Ctso* mRNA expression was not modulated by high blood pressure (Figure 2A). In cultured cells, *Ctso* mRNA was expressed in VSMC (Figure 2B) and, at weaker levels, in endothelial cells, where it was not affected by shear stress (SS) (Figure 2C, D). In VSMC, CTSO was found in cell lysates but also in the culture medium, indicating the secretion of the protein (Figure 2E). Moreover, CTSO secretion was potentiated by stretch, without any change in mRNA level (Figure 2B and Figure 2E). Interestingly, CTSO is expressed in the arterial wall of human IA domes (Figure 3A). In unruptured IA, CTSO was expressed in some endothelial cells and VSMC, but CTSO staining was not observed in ECM. A significantly higher content of CTSO, particularly in the ECM was detected in the arterial wall of ruptured IA thus confirming CTSO secretion in the extracellular space by VSMC observed *in vitro*, particularly under stretching condition (Figure 3B).

Ctso **silencing does not affect VSMC proliferation and apoptosis**

 We next aimed to elucidate the role of CTSO in the arterial wall by focusing on VSMC, in which it is predominantly expressed and its secretion is modulated by stretch. To this end, we evaluated the consequences of siRNA-mediated knockdown of endogenous CTSO in VSMC (KD-SMC) in comparison with a control siRNA pool (Cont-SMC). *Ctso* silencing did not affect VSMC proliferation (Figure 4A), nor apoptosis as measured by TUNEL and caspase 3 cleavage in basal condition (no apoptosis, data not shown) and after induction of apoptosis by

 staurosporine (Figure 4B and C). These results indicate that CTSO did not affect VSMC proliferation and viability.

Ctso **silencing modifies VSMC migration and adhesion**

 We next tested whether CTSO regulates the migratory and adhesive properties of VSMC using Boyden chambers and adhesion assays, respectively. CTSO depletion in VSMC led to a significant decrease in transmigration (Figure 4D), but accelerated the adhesion speed of VSMC on fibronectin (FN) matrix (Figure 4E). This effect was associated with an increased phosphorylation of focal adhesion kinase (FAK) in KD-SMC compared to cont-SMC, both at 2 h and 24 h after seeding on FN matrix (Figure 5A). When VSMC were plated on plastic, without FN coating, a significant increase in FAK phosphorylation was also observed at 24 h but not at 2 h post-seeding (Figure 5B). It is known that VSMC produce and release FN which, in turn, can modulate their phenotype and functions (19). The observed differences in FAK phosphorylation induced by CTSO depletion may therefore results from an effect on the endogenous FN. To test this hypothesis, we thus analyzed the effect of *Ctso* silencing on FN expression in Cont- and KD-SMC cultures. Western blot analysis revealed an increased level of FN in KD-SMC compared to Cont-SMC, while there was no difference in collagen I (COL-I) expression (Figure 5C). This rise in FN expression in KD-SMC was not associated with a change in mRNA-*Fn1* level which, like mRNA-*Col1a*, remains the same in Cont- and KD-SMC (Figure5D). The observed increase in FN level induced by CTSO silencing could therefore stem from the ability of CTSO to degrade FN. To test this hypothesis, we cultured Cont- and KD-SMC on human FN, which we quantified by immunofluorescent labeling. FN labelling confirmed the presence of a greater amount of FN in the vicinity of KD-SMC compared to Cont-SMC (Figure 5E). All together, these data show that CTSO controls VSMC migration and adhesion, and suggest that it could result from an effect on FN.

level in cell lysates was similar for WT-CTSO and the two mutated CTSO proteins (Figure

Discussion

 We have identified two rare missense variants in the *CTSO* gene shared by all the affected relatives in two large pedigrees with multiple IA-affected relative. Of note, we also observed several subjects (n=8) carrying possibly deleterious *CTSO* variations but without IA at the time of the study. In addition, we found a significant increase in the proportion of subjects with history of high blood pressure among IA carriers compared to unaffected individuals. High blood pressure history is a well-established environmental factor associated with the development of IA (22). Our results suggest, as described previously in familial cases with rare coding variants in *ANGPTL6*,(16) that rare coding variants in *CTSO* could promote IA formation in combination with other deleterious genetic or environmental factors such as high blood pressure, which would act either directly by mechanical effects on the vessel walls or indirectly by triggering inflammation (23).

 CTSO is one of the 11 cathepsins encoded in the human genome which constitute an important group of proteases that regulate numerous processes (18). Cathepsins are highly expressed in intracellular acidic compartments such as endosomes and lysosomes. Loss of function mutations in their encoding genes cause very different syndromes in terms of clinical symptoms and disease progression, corresponding to either typical lysosomal storage diseases, or resulting from defective cleavage of specific protein substrates (24). Cathepsins

 are also found in the cytoplasm, cell nucleus, cell membrane and the extracellular space (25, 26). Extracellular cathepsins mediate ECM protein degradation (collagen, elastin, fibronectin, laminin) and the release of ECM-bound factors, but also shed various membrane proteins including receptors, growth factors, cytokines, and adhesion proteins thereby influencing important cellular processes such as proliferation and differentiation, motility, cell-cell interaction, adhesion, inflammatory and immune responses. Indeed, extracellular cathepsins are majorly upregulated in pathological states and are implicated in a wide range of disorders including vascular remodeling and atherosclerotic diseases (27, 28). The cathepsins B, K and S have been found to be upregulated in the wall of IA (29). Here we observed an increase in CTSO expression, in particular in ECM, in ruptured human IA compared to unruptured IA. At cell level, CTSO is expressed in endothelial cells, and more strongly in VSMC. CTSO was found both in and around VSMC, and its extracellular release is stimulated by cell stretching, suggesting that its role as an extracellular protease in the arterial wall could be potentiated by high blood pressure and participated to the adaptive arterial remodeling induced by hypertension. The increase in CTSO expression observed in ruptured IA domes could thus result from the greater aneurysmal wall stretch induced by blood pressure in ruptured *versus* unruptured IA (30).

 CTSO is defined as a ubiquitous protein but neither its peptidase activity nor its function had been characterized yet. Although we have not analyzed the enzymatic activity of CTSO *in vitro* to directly demonstrate its ability to degrade FN, we provide a strong body of experimental evidence to support this hypothesis. Cell adhesion and FAK activation are potentiated by depletion of CTSO, both rapidly and late after VSMC seeding on exogenous FN coating, while only delayed stimulation of FAK activation was observed in CTSO- depleted VSMC seeded on plastic. These observations are consistent with a degradation of pericellular FN by CTSO, which instantaneously impaired cell-FN coating interaction in

 VSMC producing extracellular CTSO. When VSCM are seeded on plastic, the effect of CTSO depletion is only visible at late time points, after the time necessary for the cells to self- produce FN with which they establish adhesions. This hypothesis is in agreement with the increase in the amount of FN in CTSO deficient VSMC and is further supported by the strong immunofluorescence labeling of exogenous FN close to CTSO-depleted VSMC compared to its low intensity in CTSO-expressing cells. All these observations suggest that extracellular CTSO secreted by VSMC degrades FN. This was corroborated by the results obtained by the expression of the two mutated proteins p.Val316Ile-CTSO and p.Ala43Val-CTSO which, being weakly secreted, induce an increase in the amount of FN as does the depletion of CTSO. 267 It is well established that adhesive properties to ECM drives VSMC stiffness (31), and the level of activation of FAK signaling is related to VSMC stiffness (32). In particular, VSMC focal adhesions to FN correlate with VSMC stiffness (33). The strong stiffening of VSMC that we observed after CTSO depletion is therefore consistent with an increase in the ability of VSMC to form adhesions to FN due to the reduced degradation of FN in CTSO- depleted VSMC. ECM composition and organization impact the physical interactions with VSMC, which play a major role in regulating their functions, including migration and differentiation. We observed that knocking-down CTSO reduced VSMC migration on FN. This result further supports a role of CTSO in promoting FN degradation, although additional mechanisms could

also be involved such as degradation of other extracellular proteins or lysosomal degradation

of FN-bound integrins known to be required for migration.(34) Regarding VSMC

differentiation, CSTO depletion leads to increased expression of contractile phenotype marker

genes such as *Acta2*. Interestingly, deletion or inhibition of cathepsin B, characterized as a

FN-degrading protease (35) that is also up-regulated by cell stretching, also increases ACTA2

 expression through an underlying mechanism that is still unknown (36). Increased ACTA2 expression has been shown to contribute to VSMC stiffening (37), suggesting that up- regulation of *Acta2* and possibly of the other contractile markers, could participate to the increase in VSMC stiffness induced by CTSO depletion. Although contractile markers were upregulated, collagen gel contraction produced by KD-VSMC was reduced compared to Cont-VSMC. Whether this effect was related to the stiffness of VSMC induced by CTSO deletion could not be determined. Nevertheless, this possibility is supported by previous results obtained on VSMC from aged animals showing a similar association between increased stiffness (31) and reduced collagen gel contraction (33, 38). Besides their contractile activity, VSMC produce ECM that allows adaptation to mechanical forces that act on the vessel wall while maintaining adequate wall pressure (39, 40). Thus, the composition, organization and resulting interactions of ECM with VSMC are adjusted to the mechanical demands of the vessel wall through multiple and coordinated mechanisms. Among them, the fine-tuning of extracellular protease expression and activity plays a major role in ECM matrix reshaping (27). Our present study proposes that CTSO, whose secretion is regulated by cell stretch, could be a new member of these ECM proteases involved in arterial wall adaptation to mechanical stress. Indeed, we have identified CTSO as a potential new player in arterial remodeling, regulating FN deposition and VSMC function. This role of CTSO is consistent with an increased susceptibility to IA associated with non-secreted c.128C>T *CTSO* and c.946G>A *CTSO* variants. We suggest that, by promoting increased FN deposition, VSMC- FN adhesion and VSMC stiffening, the p.Val316Ile-CTSO and p.Ala43Val-CTSO mutants affect the mechanical properties of the vessel wall and compromise the proper adaptation of the

 arterial wall to local hemodynamics, thereby favoring IA formation. It is noteworthy that similar features, namely faster adhesion to FN,(41) up-regulation of contractile marker expression and

 increased stiffness, have been described in Marfan syndrome VSMC,(42) a well-known genetic condition that predisposes to IA (43).

Methods

 Sex as a biological variable. For experiments in SHR and SHRSP, only males have been used as males showed higher blood pressure and greater incidence of stroke than females (44). For analysis in humans, both males and females have been included.

 Clinical recruitment. Familial cases of IA are defined as at least two first-degree relatives both diagnosed with typical IA (defined as a saccular arterial dilatation of any size occurring at a bifurcation of the intracranial vasculature), without any age limitation. Index case subjects and their relatives were recruited according to a recruitment process previously described (45). Briefly, neuroradiological phenotyping was performed in each recruiting center by interventional neuroradiologists, neurologists, and neurosurgeons in order to recruit only case subjects with typical saccular bifurcation IA. Mycotic, fusiform-shaped, or dissecting IAs were systematically excluded, as well as IA in relation with an arteriovenous malformation and IA resulting from syndromic disorders such as Marfan disease or vascular forms of Elhers Danlos. For all included patients we recorded the date of birth, if IA, the cases of rupture, the number of IA, the IA larger diameter in mm, the IA locations according to the four following groups internal carotid artery (ICA), posterior cerebral circulation (PCA), middle cerebral artery (MCA) or anterior cerebral artery (ACA), the smoking habits, the history of high blood pressure and ischemic stroke, the level of alcohol intake per week, the history of diabetes or dyslipidemia, obesity (BMI >30), treatment by statin, antiplatelet, oral anticoagulant and anti-inflammatory drugs.

 Whole Exome Sequencing (WES). Genomic DNA was extracted from peripheral blood lymphocytes using the NucleoSpin Blood kit XL (Macherey Nagel). Whole-exome fragments were captured with the SureSelect Human All Exon V4 kit (Agilent technology), according to manufacturer protocol. Alignment on reference genome (Broad Institute human_g1k_v37) was performed using Burrow-Wheeler aligner (Bwa mem v0.7.10).(46) Picard v1.119 was used to flag duplicates and recalibration was achieved through GATK v3.2.2 (broadinstitute, 2023) (47). Variants were called with GATK HaplotypeCaller on all exons hg9 exons (NCBI RefSeq), annotated with SnpEff and vcfGnomad (jvarkit) using gnomad v2.1.(48) Quality filters detailed in the Table S1 were applied. Only variants annotated as non-synonymous or affecting splicing, and reported with a minor allelic frequency (MAF) below 0.1% in the non-Finnish European (NFE) gnomAD population, were subsequently considered.

 IBD analysis. Haplotype sharing between affected relatives were identified through IBD analysis based on SNP genotyping data. Fluorescence intensities were obtained from Precision Medicine Research Array (PMRA - Affymetrix) and quantified by Affymetrix GeneTitan Multi-Channel Instrument. Genotypes of affected relatives II.2, II9, III.2, III.4 and III.7 were merged with PREGO control population (49) and SNPs with MAF<10%, call rate < 95% or p<1.10-5 when testing for Hardy-Weinberg equilibrium were excluded. IBD regions were then identified using IBDLD v3.34 with noLD method (50). Familial segregation analysis by capillary sequencing was performed on an Applied Biosystems 3730 DNA Analyzer, using standard procedures. Sequence analyses were performed with SeqScape v.2.5.

 Human Saccular IA Samples. Saccular IA samples are from the Aneux Biobank (51). All samples were obtained during microsurgery by resection of the IA dome (i.e., the bulging

snap-frozen in liquid nitrogen for RNA extraction. WKY were used for VSMC isolation.

 *Cell culture***.** Primary VSMC were isolated from the aorta of 4-week-old WYK rats. Rats were sacrificed according to institutional animal handling ethics. The aorta was harvested, cleaned, endothelium-denuded, cut into small pieces and digested by collagenase II (1 mg/mL; 2 h at 37°C under agitation; Worthington Bio-chemical). After inactivation of collagenase with serum, the tissue was spun down and plated in a 6-well plate in Dulbecco modified Eagle medium (DMEM, Gibco; Invitrogen) containing 10% foetal bovine serum (FBS), 4.5 g/L glucose, 100 units/mL penicillin and 100 µg/mL streptomycin at 37°C-5% CO2. All

 experiments were performed at passages 2 and 3. For cell stretching, cyclic uniaxial strain was applied at 1 Hz and 10% or 20% strain for 24 hours (MechanoCulture FX, CellScale). HUVEC (passage 2 to 6; PromoCell) were routinely cultured in EBM media supplemented with the provided growth factors kit (Promocell). For flow experiments HUVEC were cultured on 0.2% gelatin-coated 0.4 ibidi slides (IBIDI) and unidirectional laminar shear stress was applied using the pumping system and control unit form IBIDI. Local shear stress 387 was calculated using Poiseuille's law and averaged to 3 dyn/cm^2 (pathological low shear 388 stress: LSS) 16 dyn/cm² (physiological shear stress: PSS) or 36 dyn/cm² (pathological high shear stress: HSS). NIH3T3 cells were cultured in DMEM containing 1 g/L glucose, 10% FBS, 100 units/mL penicillin and 100 µg/mL streptomycin at 37°C-5% CO2. *RT-qPCR.* Total RNA was purified from cells using RNA plus kit (Macherey Nagel) or tissue using TRIzol reagent (MAN0001271, Ambion, Thermo Fisher Scientific) and RNA XS Plus kit (Macherey Nagel) according to the manufacturer instructions. RNA (500 ng) was reverse- transcribed with M-MLV enzyme (28025021, Thermo Fisher Scientific). Real-time qPCR was performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems) using SYBR Green Master Mix (4367659, Applied Biosystems) and primers listed in Table S4. Each sample was analyzed in triplicate. GAPDH was used as the reference gene and results are expressed according to the $2^{-\Delta\Delta Ct}$ method. *Immunoblotting.* Supernatant from VSMC or NIH3T3 were taken off and concentrated with

 Amicon Ultra-0.5 Centrifugal Filter Unit (UFC5010, Millipore). Cells were lysed on ice in buffer supplemented with protease and phosphatase inhibitor cocktails (Sigma Aldrich) and sodium orthovanadate. Equal amount of proteins of each sample was separated by SDS-PAGE, transferred to nitrocellulose membranes, and incubated with specific antibodies:

reduction product formazan. MTT reduction by viable cells was then quantified by

measurement of the absorbance at 590 nm.

 Cell adhesion assay using impedance technology. VSMC (10000/well) were seeded in a 96 well plate microtiter xCELLigence assay plate coated with 2 µg/ml fibronectin (E-Plate, ACEA Biosciences Inc.) and placed on the Real-time xCELLigence Cell Analyzer (Roche Applied Science) platform at 37°C. The cell index value, which are proportionate to the area

 covered by the cells was measured every 5 min for a period of 8 h. Adhesion speed was defined as the slope of the cell index change over time.

 Collagen gel contraction assay. VSMC were mixed with collagen gel working solution (CBA-201, Cell Biolabs). The cell-collagen mixture was added into a 24-well plate and incubated at 37°C for 1 h to allow collagen polymerization. Serum-free DMEM was added to the top of the collagen gel lattice. After 24 h, cells were treated or not with U46619 (10^{-6}) mol/L) and the myosin inhibitor BDM (from CBA-201 kit), and the collagen gels were released by a sterile spatula. Changes in the collagen gel area were measured at 48 h. The percentage of contraction corresponded to [(area in BDM condition-area in the control or 466 U46619 condition)/ area in BDM condition \times 100].

 Immunofluorescence. VSMC were seeded onto culture plates pre-coated with human FN (F2006, Sigma-Aldrich, 20 µg/ml). After 24-hour of culture, cells were fixed with 4% paraformaldehyde for 15 min, rinsed twice with PBS, then permeabilized and blocked for 1 h with carbonate-bicarbonate buffer containing 1% FBS, 3% BSA, 0.5% Triton X-100, 0.01% deoxycholate, 0.02% sodium azide. FN was stained with anti-human FN antibody (F3648, Sigma-Aldrich; 1/500 overnight), revealed by a secondary Alexa647-conjugated donkey anti- rabbit antibody (LifeTech; 1/1000, 2 h). Actin staining was performed at room temperature using phalloidin Alexa Fluor™ 488 (A12379, Fisher Scientific; 1/400, 45 min). Images were taken using Nikon A1 confocal microscope (Nikon France, Champigny sur Marne) equipped with a x60 Plan-Apochromat objective with a numerical Aperture of 1.4. FN fluorescence was quantified using FIJI. Briefly, for each cell a mask corresponding to the cell area was generated and applied on the FN staining image. FN fluorescence intensity in this area was extracted for each cell.

 Atomic force microscopy (AFM) experiments. AFM experiments have been performed in Cont- and KD-SMC grown on plastic and allowed to produce their own ECM for 5 days. ECM analysis has been performed after decellularization as previously described (53). All experiments were then performed in Physiological Saline Solutions (PSS) buffered with 20 mM HEPES at 37°C using a NanoWizard® atomic force microscope (JPK Instruments, Germany) equipped with a temperature controller and inverted optical microscope. Indentation experiments were carried out with cantilevers (SQube) having a colloidal glass sphere of 5 µm in diameter. Their spring constant was calibrated using the thermal noise method implemented 490 in the AFM setting (JPK software), with values comprised between 0.12 and 0.15 N.m⁻¹. Prior to indentation measurements, the cantilever sensitivity was systematically measured from the slope of force-distance curves performed on glass. The optical microscope was first used to position the AFM tip on ECM or on the cytoplasmic region of the selected cell and several approach-retract force-distance curves were performed to determine the force to be applied 495 corresponding to an indentation depth of \sim 500 nm (a good compromise avoiding the long-range interactions and in the validity domain of the Hertz contact mechanics model). Then, force- distance curves were recorded on cells at a low constant speed of 1 µm/s to neglect the hydrodynamic drag forces exerted on the cantilever by the liquid medium (54). These curves were then converted into force-indentation curves, and the approach part was fitted by the Hertz model to determine the apparent elastic modulus of cells (55).

Mutagenesis. CTSO-TurboGFPpPlasmid was purchased from Origene (RG208268).

c.128C>T *CTSO* and c.946G>A *CTSO* mutagenesis was performed using Q5® Site-Directed

Mutagenesis Kit Protocol (E0554, NEB) and designed primers: A43V-Fw: 5'-GAA

GCCGCCGTCTTCCGGGAAAGTC-3'; A43V-Rv: 5'-ACG CTCGCGGCTCCGCGG-3';

- 506 V316I-Fw: 5'-GTTTGTGGTATTGCAGATTCCATTTCTTCTATATTTGTGACGC-3';
- V316I-Rv: 5'-GCGTCACAAATATAGAAGAAATGGAATCTGCAATACCACAAAC-3'.
- Mutations were confirmed by standard sequencing methods using T7 standard primer and
- designed primer (5'-AAGCCCCTGGAAGACCTAAG-3').
-
- *Generation of lentiviral constructs***.** From LT3GEPIR plasmid (#111177, Addgene), was
- modified to remove miR30 backbone by amplifying and cloning eGFP between XhoI and
- EcoRI restriction sites using the following primers: Fw 5'-
- CGGCCGCTCGAGATGGTGAGCAAGGGCGAGGAG-3'and Rv 5'
- GATCTGAATTCTTACTTGTACAGCTCGTCCATGC-3'. The resulting plasmid was used
- to clone WT and mutant CTSO in BamHI and XhoI,
-
- *Lentivirus production, transduction and induction of WT-CTSO and CTSO variants.*

Lentiviral vector for expressing WT-CTSO, p.Ala43Val-CTSO and p.Val316Ile-CTSO was

transfected into HEK293T cells along with packaging vectors psPAX2 and pVSVG2

(provided by Dr. Utz Fischer's lab) using polyethylenimine (#764965, Sigma-Aldrich)

transfection agent. After overnight incubation, the medium was replaced with fresh medium

- (DMEM+10% serum). Forty-eight hours and 72 h after transfection, viral supernatant was
- collected, filtered through 0.22 µm filter and used to infect NIH3T3 in the presence of
- polybrene (8 µg/mL, H9268; Sigma-Aldrich). After 48 to 72 h of infection, transduced
- NIH3T3 cells were selected with puromycin (2 µg/mL, P8833, Sigma-Aldrich) for 48 h and
- maintained in the presence of puromycin (2 µg/mL). The induction of WT- or mutated CTSO
- was performed at least 2 days before the experiment by supplementing the medium with
- doxycycline (1 µg/mL, #D9891, Sigma Aldrich), which was maintained until the completion
- of the experimental procedure.

- *Data availability.* All data needed to support the conclusions of this study are present in the
- paper and/or the Supplementary Materials or are available via the corresponding authors upon
- reasonable request. Values for all data points are available in the Supporting Data Values file.
-

REFERENCES

- 1. Vlak MH, Algra A, Brandenburg R, and Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. *Lancet Neurol.* 2011;10(7):626-36.
- 2. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, and Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. *Lancet Neurol.* 2009;8(7):635-42.
- 3. Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G, et al. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. *Cerebrovasc Dis.* 2013;35(2):93-112.
- 4. Vlak MH, Rinkel GJ, Greebe P, and Algra A. Risk of rupture of an intracranial aneurysm based on patient characteristics: a case-control study. *Stroke.* 2013;44(5):1256-9.
- 5. Bourcier R, Redon R, and Desal H. Genetic investigations on intracranial aneurysm: update and perspectives. *J Neuroradiol.* 2015;42(2):67-71.
- 6. Kissela BM, Sauerbeck L, Woo D, Khoury J, Carrozzella J, Pancioli A, et al. Subarachnoid hemorrhage: a preventable disease with a heritable component. *Stroke.* 2002;33(5):1321-6.
- 7. Bakker MK, van der Spek RAA, van Rheenen W, Morel S, Bourcier R, Hostettler IC, et al. Genome-wide association study of intracranial aneurysms identifies 17 risk loci and genetic overlap with clinical risk factors. *Nat Genet.* 2020;52(12):1303-13.
- 8. Bilguvar K, Yasuno K, Niemela M, Ruigrok YM, von Und Zu Fraunberg M, van Duijn CM, et al. Susceptibility loci for intracranial aneurysm in European and Japanese populations. *Nat Genet.* 2008;40(12):1472-7.
- 9. Yasuno K, Bakircioglu M, Low SK, Bilguvar K, Gaal E, Ruigrok YM, et al. Common variant near 583 the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk. *Proc Natl Acad Sci U S A.* 2011;108(49):19707-12.
- 10. Yasuno K, Bilguvar K, Bijlenga P, Low SK, Krischek B, Auburger G, et al. Genome-wide association study of intracranial aneurysm identifies three new risk loci. *Nat Genet.* 2010;42(5):420-5.
- 11. Zhou S, Ambalavanan A, Rochefort D, Xie P, Bourassa CV, Hince P, et al. RNF213 Is Associated with Intracranial Aneurysms in the French-Canadian Population. *Am J Hum Genet.* 2016;99(5):1072-85.
- 12. Santiago-Sim T, Fang X, Hennessy ML, Nalbach SV, DePalma SR, Lee MS, et al. THSD1 (Thrombospondin Type 1 Domain Containing Protein 1) Mutation in the Pathogenesis of Intracranial Aneurysm and Subarachnoid Hemorrhage. *Stroke.* 2016;47(12):3005-13.
- 13. Wu Y, Li Z, Shi Y, Chen L, Tan H, Wang Z, et al. Exome Sequencing Identifies LOXL2 Mutation as a Cause of Familial Intracranial Aneurysm. *World Neurosurg.* 2018;109:e812-e8.
- 14. Lorenzo-Betancor O, Blackburn PR, Edwards E, Vazquez-do-Campo R, Klee EW, Labbe C, et al. PCNT point mutations and familial intracranial aneurysms. *Neurology.* 2018;91(23):e2170- e81.
- 15. Yang X, Li J, Fang Y, Zhang Z, Jin D, Chen X, et al. Rho Guanine Nucleotide Exchange Factor ARHGEF17 Is a Risk Gene for Intracranial Aneurysms. *Circ Genom Precis Med.* 2018;11(7):e002099.

 16. Bourcier R, Le Scouarnec S, Bonnaud S, Karakachoff M, Bourcereau E, Heurtebise-Chretien S, et al. Rare Coding Variants in ANGPTL6 Are Associated with Familial Forms of Intracranial Aneurysm. *Am J Hum Genet.* 2018;102(1):133-41. 17. Barak T, Ristori E, Ercan-Sencicek AG, Miyagishima DF, Nelson-Williams C, Dong W, et al. PPIL4 is essential for brain angiogenesis and implicated in intracranial aneurysms in humans. *Nat Med.* 2021;27(12):2165-75. 18. Reiser J, Adair B, and Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. *J Clin Invest.* 2010;120(10):3421-31. 19. Hedin U, Bottger BA, Forsberg E, Johansson S, and Thyberg J. Diverse effects of fibronectin and laminin on phenotypic properties of cultured arterial smooth muscle cells. *J Cell Biol.* 1988;107(1):307-19. 20. Yang P, Troncone L, Augur ZM, Kim SSJ, McNeil ME, and Yu PB. The role of bone morphogenetic protein signaling in vascular calcification. *Bone.* 2020;141:115542. 21. Matsukawa H, Shinoda M, Fujii M, Uemura A, Takahashi O, and Niimi Y. Arterial stiffness as a risk factor for cerebral aneurysm. *Acta Neurol Scand.* 2014;130(6):394-9. 22. Vlak MH, Rinkel GJ, Greebe P, and Algra A. Independent risk factors for intracranial aneurysms and their joint effect: a case-control study. *Stroke.* 2013;44(4):984-7. 23. Hudson JS, Hoyne DS, and Hasan DM. Inflammation and human cerebral aneurysms: current and future treatment prospects. *Future Neurol.* 2013;8(6). 24. Ketscher A, Ketterer S, Dollwet-Mack S, Reif U, and Reinheckel T. Neuroectoderm-specific deletion of cathepsin D in mice models human inherited neuronal ceroid lipofuscinosis type 10. *Biochimie.* 2016;122:219-26. 25. Vidak E, Javorsek U, Vizovisek M, and Turk B. Cysteine Cathepsins and their Extracellular Roles: Shaping the Microenvironment. *Cells.* 2019;8(3). 26. Yadati T, Houben T, Bitorina A, and Shiri-Sverdlov R. The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management. *Cells.* 2020;9(7). 27. Liu CL, Guo J, Zhang X, Sukhova GK, Libby P, and Shi GP. Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials. *Nat Rev Cardiol.* 2018;15(6):351- 70. 28. Wu H, Du Q, Dai Q, Ge J, and Cheng X. Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases. *J Atheroscler Thromb.* 2018;25(2):111-23. 29. Aoki T, Kataoka H, Ishibashi R, Nozaki K, and Hashimoto N. Cathepsin B, K, and S are expressed in cerebral aneurysms and promote the progression of cerebral aneurysms. *Stroke.* 2008;39(9):2603-10. 30. Oliveira IL, Cardiff P, Baccin CE, and Gasche JL. A numerical investigation of the mechanics of intracranial aneurysms walls: Assessing the influence of tissue hyperelastic laws and heterogeneous properties on the stress and stretch fields. *J Mech Behav Biomed.* 2022;136:105498. 31. Lacolley P, Regnault V, and Avolio AP. Smooth muscle cell and arterial aging: basic and clinical aspects. *Cardiovasc Res.* 2018;114(4):513-28. 32. Saphirstein RJ, Gao YZ, Jensen MH, Gallant CM, Vetterkind S, Moore JR, et al. The focal adhesion: a regulated component of aortic stiffness. *PLoS One.* 2013;8(4):e62461. 33. Sehgel NL, Sun Z, Hong Z, Hunter WC, Hill MA, Vatner DE, et al. Augmented vascular smooth muscle cell stiffness and adhesion when hypertension is superimposed on aging. *Hypertension.* 2015;65(2):370-7. 34. Lobert VH, Brech A, Pedersen NM, Wesche J, Oppelt A, Malerod L, et al. Ubiquitination of alpha 5 beta 1 integrin controls fibroblast migration through lysosomal degradation of fibronectin-integrin complexes. *Dev Cell.* 2010;19(1):148-59. 35. Buck MR, Karustis DG, Day NA, Honn KV, and Sloane BF. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. *Biochem J.* 1992;282 (Pt 1)(Pt 1):273-8.

 55. Zykwinska A, Makshakova O, Gelebart P, Sinquin C, Stephant N, Colliec-Jouault S, et al. Interactions between infernan and calcium: From the molecular level to the mechanical properties of microgels. *Carbohydr Polym.* 2022;292:119629.

ACKOWLEDGEMENTS

 This work was supported by the French national research agency (ANR) (Programme d'Investissements d'Avenir ANR-16-IDEX-0007 [NeXT Initiative], ANR-21-CE17-0006 [to RBo], ANR-21-CE14-0016 [to A-CV], and ANR-15-CE17-0008-01 and ANR-23-CE14-0001 [to GL]), Fondation pour la Recherche Médicale (R22131NN - RAD22168NNA to GL), Institut de France – Académie des Sciences (Lamonica Award to GL, supporting M-AM), the Inserm and Regional Council of Pays de la Loire (to RB) and the local fund Genavie (to MF and RR). Study benefited of the framework of the AneuX project supported by grants from SystemsX.ch, and evaluated by the Swiss National Science Foundation (2014/261) exploiting the infrastructure previously elaborated during the @neurIST project supported by the 6th framework program of the European Commission (FP6-IST-2004-027703). We are grateful to the genomics (GenoA), bioinformatics (BiRD) and microscopy core facilities (MicroPICell) (SFR Bonamy, Nantes, France), members of Biogenouest and IBISA, for their expert services. We also thank the *Institut Français de Bioinformatique* (IFB; ANR-11-INBS-0013) as well as the animal house facility (UTE) of Nantes Université. We would like to thank the Genome Aggregation Database (gnomAD) and the groups that provided exome and genome variant data to this resource. A full list of contributing groups can be found at http://gnomad.broadinstitute.org/about. We acknowledge the Center of Biological Resources (CHU Nantes, Hôtel-Dieu, CBR, Nantes, France) as well as Martine Le Cunff and Marie- France Le Cunff and the Clinical Investigation Center 1413 of Nantes for their assistance in managing the ICAN and PREGO biobanks.

AUTHOR CONTRIBUTIONS

final manuscript.

 Figure 2. CTSO expression in arteries, smooth muscle and endothelial cells. (**A**) *Ctso* mRNA expression analyzed by quantitative RT-PCR in cerebral arteries of normotensive (WKY), and hypertensive rats (SHR and SHRSP). (**B**) *Ctso* mRNA expression analyzed by quantitative RT-PCR in VSMC cultured in static condition and subjected to 10% and 20% cyclic stretch. (**C**) *CTSO* mRNA expression analyzed by quantitative RT-PCR in HUVEC 757 under static condition and under flow generating low $(LSS, 3 \text{ dyn/cm}^2)$, physiological (PSS, 758 16 dyn/cm²) and very high (HSS, 36 dyn/cm²) shear stress. Means \pm SEM are shown. (**D**) CTSO expression in HUVEC under static condition and under flow (LSS, PSS and HSS) and representative Western blots. GAPDH was also blotted to check equal loading. (**E**) Representative western blots and quantification of CTSO protein expression assessed in cell lysate and culture medium of VSMC cultured in static condition and subjected to 10% and 20% cyclic stretch. (Data are expressed as mean ± SEM; ***p*<0.01 and ****p*<0.001; one-way *ANOVA*).

images of immunochemical staining of CTSO (in brown) (**A**) and quantification of CTSO

positive area (**B**) in human unruptured and ruptured IA domes. The black rectangles represent

the region shown at higher magnification in the bottom right-hand corner of each image.

771 (Results were expressed as mean \pm SEM; $*p$ < 0.05; Mann-Whitney test).

 Figure 4 Consequence of CTSO depletion on VSMC proliferation, apoptosis, migration and adhesion. (A) Proliferation assessed by the measurement of MTT absorbance in the absence and presence of 10% serum in VSMC transfected with siRNA targeting *Ctso* (KD- SMC) and control siRNA (Cont-SMC). **(B**), Number of apoptic cells in KD-SMC and Cont-779 SMC culture after stimulation with staurospaurine $(1 \mu \text{mol/L}, 8 \text{ h})$. Values represent the percentage of TUNEL-positive cells relative to total cell population in each group. **(C**) Typical Western blot of cleaved-caspase 3 in Cont- and KD-SMC and corresponding quantification. CTSO and tubulin have been also blotted to check CTSO silencing and equal loading. **(D**) Representative images of Cont- and KD-SMC which migrated to the underside surface of transwell membranes and the corresponding quantification. **(E**) Representative curve showing the cell index representing the adhesion of Cont- and KD-SMC over time and quantification of the adhesion speed. (Results were expressed relative to Cont-SMC set as 1 (except in B). Data are presented as mean ± SEM; **p* < 0.05, ***p* < 0.01; one-way *ANOVA* in A; Mann-Whitney test in (B-E)).

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.01.31.23285168;](https://doi.org/10.1101/2023.01.31.23285168) this version posted June 6, 2024. The copyright holder for this preprint

Figure 5. CTSO depletion in VSMC stimulates FAK phosphorylation and FN

 expression. (**A** and **B)** Representative Western blots showing the phosphorylation of FAK in Cont- and KD-SMC 2 h and 24 h after seeding on FN matrix (**A**) or directly on plastic (**B**). Graphs show densitometric analysis of phospho-FAK in blots, relative to FAK expression. **(C**) Representative western blots showing the amount of FN and Col-I in Cont- and KD-SMC and corresponding quantification. **(D**) RT-qPCR analysis of mRNA levels of Col1A, Fn1. Results were expressed relative to Cont-SMC and expressed as mean ± SEM (ns, Mann- Whitney test). **(E**) Representative immunofluorescent staining of human FN (purple) and phalloidin staining of actin fibers (green) in Cont- and KD-SMC (top images). Isolated FN staining is also shown (white, bottom images). SMC were seeded on human FN-coated 801 surface. Quantification of FN has been made cell by cell (each dot represents a cell, n=4 independent experiments). (Results were expressed relative to Cont-SMC and presented as mean ± SEM; **p* < 0.05, ***p* < 0.01, *****p* < 0.0001; Mann-Whitney test).

 Figure 6. CTSO depletion in VSMC modulates contractile phenotype marker expression and contraction. (A-B), RT-qPCR analysis of mRNA levels of the SMC marker genes Acta2, Myh11, Talgn, Cnn1 (**A**); and Bmp4 and Ctso (**B**) in Cont- and KD-SMC. Results 808 were expressed relative to Cont-SMC and expressed as mean \pm SEM; *p < 0.05, **p < 0.01, ***p < 0.001; Mann-Whitney test). (**C**) Representative images of Cont-SMC- and KD-SMC- seeded collagen gels 48 h after release with and without U46619 and quantification of 811 U46619-induced gel contraction in Cont- and KD-SMC. (Data are expressed as mean \pm SEM; **p* < 0.05; Mann-Whitney test).

 Figure 7. Effect of CTSO depletion and CTSO variant expression on cell stiffness and FN expression. (**A**) Atomic force microscopy determination of the elastic modulus of Cont- and KD-SMC, in the absence and presence of exogenous CTSO (200 ng/ml) (left), and their respective decellularized extracellular matrix (right). (Data are expressed as mean ± SEM; *****p* < 0.0001; one-way *ANOVA*). (**B**) Representative western blots and quantification of CTSO protein expression measured in cell lysate and culture medium of NIH3T3 expressing WT-CTSO, p.Ala43Val-CTSO and p.Val316Ile-CTSO. (**C**) Representative western blots and quantification of FN and Col-1 expression measured in WT-CTSO, p.Ala43Val-CTSO and 823 p.Val 316Ile-CTSO. (Data are expressed as mean \pm SEM; ** p <0.01 and **** p < 0.0001; one-way *ANOVA*)

825 **Tables**

826

827 **Table 1. Rare functional variants in** *CTSO* **shared by all IA-affected subjects in families** 828 **A and B.**

Predicted Functional Impact Cases / Total

829 Mutation names are based on Ensembl *CTSO* transcript ENST00000433477.3. MAF: Minor

830 Allele Frequency; NFE: Exome Aggregation Consortium (Non-Finnish Europeans);

831 GnomAD: genome Aggregation Database; GERP: Genomic Evolutionary Rate Profiling;

832 SIFT: Sorting Intolerant From Tolerant.

834 **Table 2. Clinical characteristics, treatments and exposition to risk factors for IA cases**

835 **and unaffected relatives according to** *CTSO* **status.**

836 Data are expressed as median, (minimum, and maximum) for age and as count (and

837 percentage) for all other categorical variables. The Fischer exact probability test was used for

838 contingency comparison between groups.

839